University of California at Los Angeles David Geffen School - UCLA
Welcome,         Profile    Billing    Logout  
 10 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garon, Edward
HEMONC CIRM IST Lung, NCT03546361: CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting
1
24
US
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM), Merck Sharp & Dohme LLC, LUNGevity Foundation, National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/26
01/27
KEYNOTE-E46, NCT06125197: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Recruiting
1
22
US
TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), KEYTRUDA®, pembrolizumab, pembrolizumab (MK-3475)
TILT Biotherapeutics Ltd., Merck Sharp & Dohme LLC
Lung Cancer
01/26
05/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
BASECAMP-1, NCT04981119: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Recruiting
N/A
200
US
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer
12/25
12/26
Garon, Edward Brian
RELAY, NCT02411448 / 2014-004824-22: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC

Checkmark Approval in combination with erlotinib for 1L metastatic EGFR mutation +ve NSCLC based on RELAY study
Jan 2021 - Jan 2021: Approval in combination with erlotinib for 1L metastatic EGFR mutation +ve NSCLC based on RELAY study
Checkmark Presentation of data from RELAY trial in combination with erlotinib in 1L treatment of NSCLC at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from RELAY trial in combination with erlotinib in 1L treatment of NSCLC at ESMO 2020
Checkmark Approved in combination with erlotinib for 1L metastatic EGFR mutation-positive NSCLC (based on RELAY study)
More
Active, not recruiting
3
545
Europe, Canada, Japan, US, RoW
Ramucirumab, LY3009806, Placebo, Erlotinib, Gefitinib, Osimertinib
Eli Lilly and Company
Metastatic Non-Small Cell Lung Cancer
01/19
12/25
Rothermich, Julie
No trials found

Download Options